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Introduction
Despite a few global regions with increased incidence, cancers
of the biliary tract remain a rare entity. Cholangiocarcinoma
has been referred to as an ‘orphan’ cancer, given its relative
infrequency in the Western population. Most patients are
diagnosed at an advanced disease stage which contributes
to a 5-year survival that is less than 10% (1). Although
cholangiocarcinoma remains relatively rare, the incidence of
intrahepatic cholangiocarcinoma has been rising worldwide
over the past decade (2) and thanks to the relentless advocacy
efforts of the Cholangiocarcinoma Foundation and focused
research from a few investigators, advances in the molecular
description of the entity have recently been seen (3). The
potential for targeted therapies to address several mutational
changes, added to the new discoveries in immunotherapy
has led experts to rethink the entity of biliary cancers and to
view the disease through a new lens as summarized herein.
This communique summarizes the thoughts of some of the
world’s experts in biliary cancer as they challenged each
other in debates and lecture discussions on multi-varied
subjects as part of the Third Annual Cholangiocarcinoma
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Foundation Meeting that was held in Salt Lake City, Utah
between February 3 and 5, 2016.
Surgical resection and liver transplantation
Surgical resection of cholangiocarcinoma remains the only
potentially curable therapy and is rarely feasible except
in extrahepatic cholangiocarcinoma where tumors are
commonly located at or near the junction of the left and
right hepatic ducts. This location at the biliary confluence
near the bifurcation of the portal vein and the right hepatic
artery accounts for the challenges of adequate surgical
resection. Even in the absence of distant spread, achieving
negative bile duct margins, leaving behind adequate liver
remnant function, and maintaining adequate portal and
arterial inflow to the liver remnant is a difficult task. When
resection is being considered, the goal is to completely
remove all tumor tissue (R0 resection) maintaining an
adequate liver remnant. An incomplete (R2: grossly involved
margin) resection is probably futile and any potential benefit
too small to justify the surgical risk. The biliary extent of
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the tumor should allow a margin negative resection and
permit technically feasible reconstruction of the biliary
tree, with an adequate remnant liver volume, usually at
least 30% of the total liver volume. Studies examining
the outcomes of patients with cholangiocarcinoma who
undergo surgery with curative intent find a median overall
survival of 34 months. Several prognostic factors may
identify subgroups of patients with better survival. In
patients with R0 resection, median overall survival rates of
60 to 65 months are reported. In addition, a negative lymph
node status, well-differentiated tumor grade, and papillary
phenotype are independent predictors of favorable survival.
Unfortunately the high rate of recurrence in the remnant
liver is associated with a 5-year survival of only 20–30% in
most series of patients undergoing partial hepatic resection.
This has led to investigation of liver transplantation as a
strategy for curative therapy for this dismal disease. Current
reports using neoadjuvant chemoradiation in conjunction
with liver transplantation demonstrate 5-year survival
rates of 50–70% in highly selected patients with hilar
cholangiocarcinoma (4). Current criteria include use of this
approach in patients with unresectable tumors less than
3 cm in greatest dimension, in the absence of intrahepatic
or regional nodal involvement, and in whom transperitoneal
biopsies have not been performed. While promising, this
approach can only be utilized in highly selected patients.
Improved diagnostic studies and earlier detection are greatly
needed to allow more patients to be eligible for curative
therapy. Intrahepatic cholangiocarcinoma is generally
considered a contraindication for liver transplantation at
most centers, however results for patients with solitary
tumors less than 3 cm in size, in the setting of underlying
cirrhosis, suggest that this therapy has similar success rates
to transplantation in patients undergoing transplant for
hilar tumors. While efforts continue to help better define
the role of transplantation, future studies should also focus
on refining surgical techniques, expanding minimally
invasive approaches, and finding better adjuvant treatments
to reduce the high recurrence rate.
Adjuvant therapy for cholangiocarcinoma:
different views
The role of adjuvant therapy following curative resection
of cholangiocarcinoma is uncertain. While some cancer
characteristics have been identified which clearly increase
the risk for tumor recurrence (1)—multifocality, lymph node
and margin-positive disease—the rarity and heterogeneity
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of the disease has made the conduct of classic randomized
studies very difficult. Therefore adjuvant therapy guidelines
reflect consensus statements and literature reviews; for
example, patients in whom adjuvant therapy did not provide
a significant improvement in survival (5). Within this report,
a subset analysis suggested that patients who were left with
positive lymph nodes or R1 resection margins derived the
most benefit for adjuvant chemoradiation or chemotherapy.
But the applicability of this observation has the limitation of
any retrospective data set, reflecting the lack of consistency
in the extent and details of surgery. A very small number of
intrahepatic cholangiocarcinoma cases were included in this
meta-analysis and therefore the benefit of adjuvant therapy
in intrahepatic cholangiocarcinoma is unproven. In cases
of extrahepatic (hilar) cholangiocarcinoma, the Mayo clinic
experience has highlighted the role of liver transplantation
in those with unresectable disease (4). While there are a
range of opinions, until there are better data available, the
presented meta-analysis by Horgan et al. makes reasonable
and rationale recommendations for managing patients.
Similarly, the role for radiation for cholangiocarcinoma
has come under scrutiny; recommendations largely stem
from observations that radiotherapy does not affect survival
in pancreatic cancer, which is the data source behind much
of the rationale. However, larger scale genomic studies
confirm that cholangiocarcinoma has much lower rates
of mutant KRAS, which preclinical studies have shown
confers radio-resistance (6-8). This observation is backed
by clinical observations that mutant KRAS tumors have
worse outcomes than wild type KRAS in rectal cancer,
lung stereotactic body radiation therapy (SBRT), and
liver SBRT. Additionally, local control, particularly in
extrahepatic cholangiocarcinoma, appears to be a dominant
failure pattern, and associated with quality of life issues.
More data that supports the role of radiation include the
recently published phase II study of protons in inoperable
intrahepatic cholangiocarcinoma demonstrating 2-yr local
control of 95% (9). Additionally, a study by Southwest
Oncology Co-operative Group (SWOG) evaluating
gemcitabine plus capecitabine followed by chemoradiation
demonstrated a much lower local failure than historical
surgical series (10). Further formal evaluations of the role of
radiation in cholangiocarcinoma are needed.
In summar y, adjuvan t tr eatmen t with s y s t em i c
chemotherapy or chemoradiation is still not standard of
care for most patients with cholangiocarcinoma. Patients
with multifocal, node or margin positive disease should be
considered for clinical trials of adjuvant therapy. Ongoing
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international trials will offer insight in this regard. The
recent SWOG phase II trial enrolled patients with
extrahepatic cholangiocarcinoma or gallbladder cancer who
were treated with systemic chemotherapy (gemcitabine
plus capecitabine) followed by chemoradiation (5). A total
of 79 eligible patients were treated; the 2-year survival was
65%, whereas it was 67% and 60% in R0 and R1 patients,
respectively. Median overall survival was 35 months. This
regimen is therefore considered as effective as an adjuvant
approach. The same group has planned a randomized
controlled trial for extrahepatic cholangiocarcinoma.
Targeted therapeutics represents a promising strategy for
advanced cholangiocarcinoma. Recent genomic sequencing
studies have identified a host of genetic aberrations that are
potentially targetable. These include ERBB2, IDH1, FGFR
and B-RAF mutations (6,11,12).
Systemic therapy: one-size fits all or custom-made
therapy?
In the setting of advanced (locally advanced, recurrent or
metastatic) biliary tract cancers, systemic chemotherapy with
gemcitabine plus cisplatin has become the reference regimen,
based on the results of the ABC-02 study (13). In this study,
patients who met standard eligibility criteria (e.g., performance
status 0–1, baseline bilirubin level ≤1.5× upper limit of normal
and adequate renal function) were included as long as the
cancer was biliary in origin. While it is widely acknowledged
that within the term “cholangiocarcinoma” there are different
subgroups of patients based on anatomy—intrahepatic,
extrahepatic and gallbladder—as well as on different molecular
signatures (14), an assessment of the magnitude of benefit
of gemcitabine plus cisplatin was constant in ABC-02 across
the different diagnoses, an effect maintained when Japanese
patients were also evaluated (15). This confuses the question
of whether to look at the entire population or at subsets when
exploring new treatment options.
The establishment of standard chemotherapy regimens
for cholangiocarcinoma is a recent phenomenon (the first
effective cholangiocarcinoma regimen was identified in
2010 vs. the first regimens for colorectal cancer established
in the 1950s). Fluoropyrimidines (5-FU and capecitabine)
along with gemcitabine and platinum compounds appear
to be active. However, to date, no biomarkers have been
identified to predict who will respond to chemotherapy, and
the pressures to find active therapies are balanced against
the challenges of improving outcomes in patients who often
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have disease courses complicated by compromised liver
function and infections, for example.
On the other hand, there are “actionable” targets in the
biliary tract. The first generation of studies has targeted the
epithelial growth factor receptor. Despite the encouraging
results of the early phase II, single arm study of cetuximab
in addition to the gemcitabine/oxaliplatin combination
(GemOx) (16), four randomized studies [adding cetuximab
(two studies) (17,18) erlotinib (19) or panitumumab (20)
respectively to the GemOx regimen] have now failed to
demonstrate a PFS or OS improvement over chemotherapy
alone, highlighting the need for randomized trials to
truly evaluate the potential benefit of novel agents.
Retrospectively, it will be important to identify, if possible,
if there were any subgroups of patients who did derive
benefit within the whole study population of those studies.
At present, chemotherapy as a “one-size-fits all” remains
one of the cornerstone of treatment (along with surgery
and radiotherapy); much as it remains in other cancers
such as breast cancer, colorectal cancer and lung cancer
where targeted therapies are also being increasingly used.
However, advances in DNA sequencing technologies
have enabled the identification of common tumor
mutations in biliary tract cancers, including IDH1, IDH2,
FGFR2, mismatch repair proteins, and ERBB2 (21,22).
The frequency of certain mutations is associated with
tumor location, with significantly different incidences for
intrahepatic, extrahepatic, and gall bladder sites of cancer.
The genetic heterogeneity between individual biliary tract
cancers suggests that treatment should be individualized,
or “custom-made”, according to tumor mutation status
in some cases. In support of this hypothesis, clinical trials
of several novel targeted agents for genetically-defined
subsets of biliary tract cancers show promising efficacy,
including the IDH1 inhibitor, AG-120, for IDH-1-mutant
cholangiocarcinoma (23), the pan-FGFR inhibitor BGJ398
for intrahepatic cholangiocarcinoma harboring FGFR2
gene fusions or other FGFR pathway aberrations (24),
and the immune checkpoint inhibitor pembrolizumab
for biliary tract cancers with defects in mismatch repair
genes (25). These exciting data support ongoing efforts to
better define anatomic, molecular, and genetic subsets of
biliary tract cancers for stratification and enrichment in
clinical trials of targeted therapies to identify patients most
likely to respond, so that we may move towards custommade therapy for patients suffering from this complex and
heterogeneous family of cancers.
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Molecular profiling of biliary cancers: the future
of therapy
Whole exome and transcriptome sequencing of biliary tract
cancers has provided key insights into the heterogeneity
of molecular alterations among cancers arising at different
sites along the biliary tract and a strong rationale for the
development of molecularly targeted therapies. While
FGFR2 gene fusions and IDH1/2 and BAP1 mutations
are found in intrahepatic cholangiocarcinoma, PRKACA/
PRKACB fusions, ELF3 and ARID1B mutations occur
preferentially in extrahepatic cholangiocarcinoma while
aberrations in ERBB2/3, EGFR, PTEN and mutations in
TERT promoter gene have been described in gallbladder
cancers (26). A poor prognosis subtype characterized by
high mutational load and increased immune checkpoint
activity has been identified across all sites, and may predict
for response to immune checkpoint inhibitors. Optimally,
patients will be selected for targeted therapy based on
molecular profiling. Ongoing clinical trials are evaluating
the use of TRK, ALK and ROS-1 inhibitors in patients
with NTRK or ROS-1 rearrangements, and FGFR
inhibitors in patients with FGFR2 fusions, while inhibitors
of IDH1/2 and ERBB2/3 are also in clinical development in
genetically selected populations. The wealth of therapeutic
targets identified by molecular profiling offers promise for
integration of targeted therapy with chemotherapy, and
hopes for a significant improvement in patient outcomes
over the coming decade.
Based on the previous section, one may wonder
if molecular profiling is justified for all patients with
cholangiocarcinoma at this point in time. The end goal of
tumor profiling is the application of personalized medicine
to optimize therapeutic benefit and minimize toxicity or
unnecessary exposure to side effects. The application of
molecular profiling for the treatment of biliary cancers faces
challenges related to the heterogeneity of the disease, the
prioritization of targets as well as identification of driver
alterations, the clonal evolution of cancer and several other
microenvironment and stromal pressures which impact the
biology of this cancer in a global manner. It has become
clear that relevant therapeutic targets can be elucidated
through molecular profiling such fusions in FGFR or
mutations in IDH1 and amplifications in Her2. These
continue to be relatively rare and vary based on the site of
origin of the biliary cancer (intra-versus extrahepatic). To
optimize the application of molecular profiling, it would be
prudent to follow careful algorithms to prioritize molecular
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alterations, to account for tumor heterogeneity and clonal
evolution (possibly through liquid biopsies), and to account
for the effect of the epigenome and the microenvironment
on the tumor. Lastly, emerging research suggests that
integrative molecular analysis approaches can help to
classify biliary cancers into specific subgroups with distinct
molecular signatures that are associated with prognosis and
that may in turn offer opportunities for tailored treatment
approaches aimed at more global signatures. In summary,
there is jewel in the haystack as some molecular alterations
may offer excellent therapeutic opportunities but advancing
the treatment of this complex disease also requires a more
global understanding of the biology and likely combinations
of therapies.
A special type of intrahepatic cholangiocarcinoma:
fluke-worm related cholangiocarcinoma
Liver flukes are the foodborne parasites dwelling in the
biliary tract. Based on epidemiologic data and animal
models, the infection of two liver flukes, Opisthorchis
viverrini and Clonorchis sinensis, is strongly associated with
intrahepatic cholangiocarcinoma in humans. People get
infected with liver flukes by eating raw freshwater fish, and
it has been hypothesized that chronic fluke infection and
both endo- and exogenous nitrosamine formation causes
intrahepatic cholangiocarcinoma in Northeastern Thailand,
with the world’s highest incidence of the disease. Although,
the “top-down” mass anti-helminthic therapy could
lower the infection prevalence in the past two decades,
re-infection is still the major challenge for intrahepatic
cholangiocarcinoma prevention. Therefore, researchers
at Khon-Kaen University have initiated a “bottom up”
strategy to establish a durable healthy ecosystem led by the
community. Following the successful pilot project, it has
been expanded to other areas in Northeastern Thailand (27).
Although the clinical presentations of fluke-associated
intrahepatic cholangiocarcinoma are similar to nonfluke associated ones, fluke-associated intrahepatic
cholangiocarcinoma tend to occur at the hilar or perihilar
bile ducts. Molecular differences between fluke- and nonfluke associated with intrahepatic cholangiocarcinoma
have been identified in mRNA expression, gene mutation
and microRNA expression profiles. Currently, there is no
difference in management of fluke- and non-fluke associated
intrahepatic cholangiocarcinoma. However, based on
molecular differences, we can look forward to different
treatment for these two entities.
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The potential for immunotherapy in biliary tract
cancer
Immune checkpoint inhibition leads to durable tumor
control and shrinkage in a subset of patients with a variety
of advanced malignancies. Immune checkpoint blockade
has translated into a significant overall survival advantage
in comparison to established therapies in some metastatic
solid tumors (28). A critical question is whether immune
checkpoint blockade will lead to clinical benefit and improved
survival in patients with cholangiocarcinoma. Emerging
preclinical data suggest that a subset of biliary tract cancers
are recognized by the immune system but undergo a complex
process of immune editing, which allows biliary tract cancers
to evade an anticancer immune response. Furthermore,
stromal factors, such as carcinoma associated fibroblasts,
may exclude and exhaust effector T lymphocytes, leading to
biliary tract cancers’ immune privilege. Preliminary clinical
data indicate that some patients with biliary tract cancers
respond to immune checkpoint blockade and several studies
are now planned or ongoing to define the role of this novel
therapeutic approach.
CCA genetics and cancer detection
The major identified risk factors for CCA are underlying
inflammatory disorders, and transcriptional profiling of
intrahepatic CCA has revealed a subset of cancers with
an inflammatory STAT3 signature. In addition, genome
sequencing studies suggest that chromatin modifiers are
frequently disrupted in this disease suggesting intrahepatic
CCA may be a disease of epigenetic chromatin modification.
Gain-of-function mutations in the isocitrate dehydrogenase
(IDH) gene are one potential mechanism for epigenetic
dysregulation, as the mutant enzyme catalyzes the formation
of the oncometabolite 2-hydroxyglutaric acid, which
inhibits histone demethylases. Mutations in IDH are rare
in most epithelial tumors but relatively common in CCA,
and trials with IDH inhibitors for patients with activating
mutations are underway. Fibroblast growth factor receptor
2 (FGFR2) fusions are also common in intrahepatic CCA,
and recent studies suggest that the pan-FGFR inhibitor
BGJ398 may be active in treating cancers with these gene
fusion aberrations (29). In contrast to intrahepatic CCA,
PRKACA and PRKACB fusion genes are common in
perihilar CCA and presumably are targetable. CCA is also a
highly desmoplastic cancer with a rich stroma characterized
by cancer associated fibroblasts (CAF). Preclinical data
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suggest that CAF are susceptible to a class of drugs termed
BH3 mimetics and that targeting CAF with these agents
may have an anti-tumor effect in CCA (30).
The analysis of 38 CCA samples from The Cancer
Genome Atlas project (TCGA), including mutations,
methylation, copy number, RNA, miRNA, and protein
platforms was reported (Lawrence N. Kwong, new
unpublished data). A meta-analysis of all published
sequencing data to date in >500 fluke-negative intrahepatic
cholangiocarcinoma samples revealed potential mutual
exclusivity of PIK3CA and TP53 mutations as well as KRAS
and IDH mutations. Should these exclusivities hold up in
larger cohorts, they could form a partial basis for classifying
cholangiocarcinoma with therapeutic implications given the
rapid development of PI3K pathway, MAPK pathway, and
IDH inhibitors? The TCGA analysis identified a distinct
cross-platform signature of IDH mutant samples which
included specific copy number profiles, methylation profiles,
and most critically, expression profiles that were enriched
for increased oxidative phosphorylation and decreased
chromatin modifier signatures. Moreover, several IDH-wild
type samples were found to resemble IDH mutant samples
in both expression and copy number profile. Overall,
these studies provide an initial step towards identifying
clinically-relevant molecular classifications of intrahepatic
cholangiocarcinoma with therapeutic implications given
recent and ongoing efforts to develop inhibitors of oxidative
phosphorylation epigenetic modifiers.
Using the paradigm of pancreatic cancer, another
highly lethal malignancy for which most patients are
unresectable at the time of diagnosis, early detection of
cholangiocarcinoma could employ the same leukopheresis
to enrich the number of cells recovered. Rhim described
efforts to detect tumor-associated DNA sequences in
patient-derived material, including circulating tumor cells
(CTCs), exosomes, and as cell free DNA in the plasma.
Digital droplet PCR, which allows for highly sensitive
amplification of DNA when a template is present, has
been adapted for this so that approximately 250 different
amplicons of interest can be amplified for sequencing.
Metabolism and epigenetics
With respect to mutant IDH, metabolism is important.
By focusing on metabolic pathways that are limiting for
the proliferation of cancer cells in different environmental
and tissue contexts, Vander Heiden found that nucleotide
synthesis is often limiting, and that the tumor cell of origin
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and tissue microenvironment dictate how cells generate
nucleotides. For example, in many tumors access to
oxygen or other electron acceptors limits the production
of aspartate, which is necessary for purine, pyrimidine and
protein synthesis. Further underscoring the importance of
the environment in dictating cell metabolism, tumor cells
grown in vitro predominantly rely on glutamine as a carbon
source while many of the same cells growing in vivo rely less
on exogenous glutamine as a fuel source.
At the interface of epigenetics and genetics, Whetstine
presented data showing that in addition to changes in
chromatin, the lysine demethylase Jmjd2a (KDM4a) could
also drive changes in copy number in specific regions of the
genome. Surprisingly, these changes in copy number were
reversible. Whetstine proposed that reversible copy number
changes may be a mechanism employed by normal cells
to respond to stress (hypoxia in particular) and that cancer
cells may co-opt the process during progression.
Animal models
The liver is well known for its regenerative capacity, which
under normal circumstances is mediated by the replication of
existing cells. What has become clear over the last few years
is that many forms of liver injury are also accompanied by
substantial cellular plasticity, whereby hepatocytes become
converted into cells with many or most cholangiocyte
features. This phenomenon of cellular plasticity was touched
upon in several talks from the last session, which dealt with
the use of preclinical models of CCA.
Cholangiocarcinoma can originate from hepatocytes
in mice (31). Hepatocytes were labeled and then exposed
to activated Notch and Akt signaling. This resulted in the
development of tumors with histological and molecular
features of intrahepatic cholangiocarcinoma. Because the
tumor cells bore the hepatocyte lineage label, this provided
unambiguous evidence that the tumors had arisen from
hepatocytes, and work from other groups has supported this
finding (32). Willenbring went on to discuss work regarding
the role of plasticity in normal liver regeneration, showing
that hepatocytes can also give rise to biliary cells in a genetic
model of bile duct paucity.
Data also suggest that intrahepatic cholangiocarcinoma
can also arise from cholangiocytes (33). Forbes used a strain
of mice in which Cre recombinase could be activated in
cholangiocytes in a tamoxifen-inducible manner (CK19CreER). Using this strain, in combination with a lineage
marker, his group deleted p53 specifically in the biliary
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compartment. When these manipulations were combined
with administration of the carcinogen thioacetamide (TAA),
they developed intrahepatic cholangiocarcinomas over a
6-month period, demonstrated a clear biliary origin of the
tumors. Based on these studies, it appears that intrahepatic
cholangiocarcinoma can arise from either cholangiocytes
or hepatocytes in the right context. Forbes also showed
data regarding the role of Wnt and Notch signaling in
CCA pathogenesis. Analysis of human tissue revealed
that the stromal macrophages surrounding intrahepatic
cholangiocarcinomas express Wnt ligands. Moreover, the Wnt
pathway activity progressively increases during pre-malignant
progression, suggesting that Wnt pathway inhibitors (e.g.,
inhibitors of the Wnt regulator porcupine) could have
therapeutic benefit in CCA.
Obviously there are pros and cons to the various model
systems. In particular, one may ask if the genetically
engineered models and patient-derived xenograft (PDX)
models adequately capture the complex intra- and intertumoral biology of CCA that will be necessary to move
therapies forward. Andersen suggested that increased
access to patient samples was the best way to understand
the biology and therefore generate progress, and to this
end described a number of efforts underway to molecularly
characterize human CCA.
Saha reviewed the work of the group to create a
genetically engineered mouse model of CCA which
incorporates mutations in IDH and Kras (34) and then went
on to describe a high-throughput screen in which a panel
of CCA cell lines was pitted against a library of clinicallyrelevant compounds. Comparing the responses of the CCA
cell lines to those of >600 cell lines derived from other
solid tumor types revealed that CCA lines bearing IDH
mutations had a distinct response profile. In particular,
mutant CCA cells exhibited extreme sensitivity to a class of
kinase inhibitors. By applying CRISPR/Cas9-based genome
editing, the key mediators of drug sensitivity were defined,
enabling the creation of a new clinical trial for intrahepatic
cholangiocarcinoma patients with IDH mutations.
CCF grant recipient talks
In 2015, the CCF awarded its first research fellowships—
one-year grants to junior investigators to pursue CCA
research and the first afternoon session featured four short
talks by the first cohort of Fellowship recipients. Allyson
Merrell began by speaking about the cellular origins of
CCA, an area of some controversy in the field. Because
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CCA exhibits histological features of ducts, tumors were
thought to arise from duct-lining cholangiocytes (or
biliary epithelial cells). However, different laboratories
have shown, using lineage tracing in the mouse, that both
hepatocytes and biliary epithelial cells can give rise to CCA
depending on the oncogenes used and other experimental
details. Merrell is systematically testing different mutations
in both cell types to clarify the connection between cell of
origin, mutational spectrum, and resulting tumor type. As
cellular plasticity is an important feature of normal liver
injury, these findings may reflect a connection between
the multiple cells of origin and the frequent mutation of
epigenetic regulators in CCA.
Next, Katsuyuki Miyabe spoke about his studies
regarding fibroblast growth factor receptor (FGFR) gene
family aberrations in CCA, hypothesizing that FGF
receptor aberrations other than the known mutations in
FGFR2 might play a pathogenic role. RNA sequencing of
9 cases of CCA samples showed that several FGF ligands
and FGF receptor 4 (FGFR4) are expressed at significantly
lower levels when compared to 119 normal liver samples
from the GTex database. Moreover, RNA sequencing has
also detected new fusions of potential interest. Miyabe
found that multiple FGFR inhibitors (ponatinib, dovitinib,
BGJ398) inhibited the growth of LIV31 CCA xenografts
(with FGFR fusions), with BGJ398 being the most potent.
This xenograft model could be used in the future to select
the FGFR inhibitor which works best for a given patient’s
fusion.
Daniela Sia provided further insight into the role of
FGFR2 fusions in CCA. As prior work showed a novel
FGFR2 fusion event (FGFR2-PPHLN1) in 16% of
intrahepatic cholangiocarcinoma patients (35), Sia tested the
impact of this aberration by injecting mice with FGFR2PPHLN1—expressing cells, showing enhanced tumor
growth rates compared to mice injected with empty vector.
The most dramatic effects were seen during the initial
phase of tumor growth. Treatment of FGFR2-PPHLN1—
expressing HUCCT1 xenografts with a FGFR2 inhibitor,
BGJ398, induced decreased tumor growth compared
to the placebo group with no apparent signs of toxicity.
Similar efficacy of BGJ398 was observed in vitro in cell lines
expressing other FGFR fusion proteins, including FGFR2BICC1.
Chad Walesky described how he is using the zebrafish
to study the influence of developmental pathways on CCA
pathogenesis. Specifically, he is focusing on potential
interactions between the Wnt/β-catenin pathway and
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hepatocyte nuclear factor 4 alpha (HNF4α), molecules
that are involved in the development of the liver as well
as CCA (35-40). Studies in the laboratory have shown
that knockdown of HNF4α in the zebrafish leads to a
reduction in hepatocyte differentiation while genetic or
chemical increase in β-catenin results in a loss of HNF4α
and a maintenance of cholangiocyte differentiation. Based
on these findings, it is hypothesized that activation of
β-catenin results in a loss of HNF4, causing hepatoblasts to
preferentially differentiate into cholangiocytes.
Conclusions
The work described herein gives an in-depth summary of
the current approaches to treatment and translation for
cholangiocarcinoma. This conference also brought together
a broad collection of clinical and scientific investigators
sharing the common goal of understanding and combatting
cholangiocarcinoma. As exemplified by several of the talks,
this type of fundamental understanding has already led to
the development of patient-specific therapeutic approaches
that can be tested in clinical trials. Other approaches,
including immun otherapy, are viewed with great
excitement, but will require more of the same type of basic
understanding for progress to be made. More importantly,
it helps identify the unanswered questions and challenges
which require cross-disciplinary collaboration and strong
advocacy to resolve and overcome.
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